Clinical Trials Logo

Thrombocythemia clinical trials

View clinical trials related to Thrombocythemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT04821791 Recruiting - Myelofibrosis Clinical Trials

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. (LIMBER-213)

Start date: March 31, 2021
Phase: Phase 2
Study type: Interventional

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

NCT ID: NCT04629508 Completed - Myelofibrosis Clinical Trials

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Start date: July 12, 2021
Phase: Phase 2
Study type: Interventional

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

NCT ID: NCT02308787 Completed - Clinical trials for Myeloproliferative Disease

Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions

PLTD
Start date: November 2014
Phase: N/A
Study type: Observational

Multicenter, Retrospective Data Collection of Routine Clinical Use with the Spectra Optia® Apheresis System for Platelet Depletion Procedures.

NCT ID: NCT00946270 Completed - Polycythemia Vera Clinical Trials

Pomalidomide for Myelofibrosis Patients

Start date: July 22, 2009
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if CC-4047 (now called pomalidomide) and prednisone can help to control MMM. The safety of this therapy will also be studied.

NCT ID: NCT00175838 Completed - Clinical trials for Myeloproliferative Disorder

Primary Thrombocythaemia 1 Trial

PT-1
Start date: July 1997
Phase: N/A
Study type: Interventional

The purpose of this trial is to see if Hydroxyurea + aspirin is a better treatment than aspirin alone for Intermediate Risk Primary Thrombocythemia (PT) patients.